Acadia Pharmaceuticals (ACAD) Depreciation and Depletion (2010 - 2026)
Acadia Pharmaceuticals (ACAD) recorded quarterly Depreciation and Depletion of $271000.0 in Q1 2026, up 17.32% quarter-over-quarter from $231000.0 in Q4 2025, and up 18.34% on a YoY basis from $229000.0 in Q1 2025.
Acadia Pharmaceuticals (ACAD) Depreciation and Depletion (2010 - 2026) Analysis & Trends
Acadia Pharmaceuticals' Depreciation and Depletion history runs 17 years deep, the most recent figure standing at $271000.0 for Q1 2026.
- In Q1 2026, Depreciation and Depletion rose 18.34% year-over-year to $271000.0; the TTM figure through Mar 2026 stood at $942000.0 (up 3.86% YoY), while the FY2025 annual figure was $900000.0, down 2.17% from the prior year.
- Depreciation and Depletion was $271000.0 for Q1 2026 at Acadia Pharmaceuticals, up from $231000.0 in the prior quarter.
- In the past five years, Depreciation and Depletion ranged from a high of $516000.0 in Q1 2022 to a low of $213000.0 in Q2 2025.
- Historically, Depreciation and Depletion has averaged $326470.6 across 5 years, with a median of $271000.0 in 2026.
- The sharpest annual moves came in 2024 and 2026: Depreciation and Depletion tumbled 43.78% in 2024, then increased 18.34% in 2026.
- A 5-year view of Depreciation and Depletion shows it stood at $463000.0 in 2022, then plunged by 41.25% to $272000.0 in 2023, then retreated by 16.91% to $226000.0 in 2024, then gained by 2.21% to $231000.0 in 2025, then grew by 17.32% to $271000.0 in 2026.
- The last three Depreciation and Depletion figures came in at $271000.0 (Q1 2026), $231000.0 (Q4 2025), and $227000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation and Depletion (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1,395.22 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Acadia Pharmaceuticals | 3.68 Bn | 2.83 Bn | 243.27 Mn | 271,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 271,000.00 |
| Mar 31, 2026 | 271,000.00 |
| Dec 31, 2025 | 231,000.00 |
| Dec 31, 2025 | 231,000.00 |
| Sep 30, 2025 | 227,000.00 |
| Sep 30, 2025 | 227,000.00 |
| Jun 30, 2025 | 213,000.00 |
| Jun 30, 2025 | 213,000.00 |
| Mar 31, 2025 | 229,000.00 |
| Mar 31, 2025 | 229,000.00 |
| Dec 31, 2024 | 226,000.00 |
| Dec 31, 2024 | 226,000.00 |
| Sep 30, 2024 | 226,000.00 |
| Sep 30, 2024 | 226,000.00 |
| Jun 30, 2024 | 226,000.00 |
| Jun 30, 2024 | 226,000.00 |
| Mar 31, 2024 | 242,000.00 |
| Mar 31, 2024 | 242,000.00 |
| Dec 31, 2023 | 272,000.00 |
| Dec 31, 2023 | 272,000.00 |